Acrivon Therapeutics, Inc. Share Price
NASDAQ: ACRV | Micro CapAcrivon Therapeutics, Inc. Stock Performance
Open $1.73 | Prev. Close $1.69 | Circuit Range N/A |
Day Range $1.72 - $1.75 | Year Range $1.21 - $3.54 | Volume 9,216 |
Average Traded $1.73 |
Acrivon Therapeutics, Inc. Share Price Today
As of 10 August 2026, Acrivon Therapeutics, Inc.'s share price is $1.74. The stock opened at $1.73, compared to its previous close of $1.69. During today's trading session, Acrivon Therapeutics, Inc.'s share price traded between $1.72 and $1.75, with an average price of $1.73. Over the past 52 weeks, the stock has recorded a high of $3.54 and a low of $1.21. In terms of performance, Acrivon Therapeutics, Inc.'s share price has risen by 14.85% over the last six months and is up 28.89% on a year-on-year basis.
Acrivon Therapeutics, Inc. Share Price Chart
Acrivon Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $67.01M | PE Ratio (TTM) -0.86 | Dividend Yield N/A |
EPS (TTM) $-2.02 | Revenue (TTM) N/A | Return On Equity (TTM) -69.24% |
Profit Margin N/A | Debt to Equity 0.14 | Quarterly Earnings Growth YoY 18.75% |
Acrivon Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Acrivon Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Acrivon Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.49 | $1.73 | +14.57% |
Jul 2026 | $1.77 | $1.51 | -15.17% |
Jun 2026 | $1.58 | $1.78 | +10.22% |
May 2026 | $1.88 | $1.61 | -12.70% |
Apr 2026 | $1.46 | $1.85 | +32.14% |
Mar 2026 | $1.48 | $1.40 | -7.59% |
Feb 2026 | $1.75 | $1.51 | -15.13% |
Jan 2026 | $2.39 | $1.78 | -26.09% |
Dec 2025 | $2.37 | $2.42 | +1.90% |
Nov 2025 | $2.26 | $2.37 | +19.70% |
Oct 2025 | $1.85 | $1.98 | +8.20% |
Sep 2025 | $1.32 | $1.83 | +35.56% |
ACRV Share Price FAQs
What is Acrivon Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Acrivon Therapeutics, Inc. stock?
What is ACRV's market capitalisation today?
What is ACRV's net income for the last quarter?
What is the 5 year returns of ACRV?
What is the high & low stock price of ACRV today?
Can I buy ACRV shares in India?